Quantum Biopharma Licensee Celly Nutrition Retains Leading New York Investment Bank to Advise on Capital Raise and Possible Initial Public Offering Following Highly Positive Results from unbuzzd™ Clinical Study
Quantum BioPharma (NASDAQ: QNTM) announced that its licensee Celly Nutrition , developer of unbuzzd™ (a beverage that accelerates alcohol metabolism), has engaged a leading New York Investment Bank to raise up to $10 million USD and explore an IPO on a major US exchange.
Quantum BioPharma owns 25.71% of Celly Nutrition and receives 7% royalty on unbuzzd™ sales until reaching $250 million, after which it drops to 3% in perpetuity. The company retains full rights to develop similar products for pharmaceutical and medical uses.
The Letter of Engagement signed on February 4, 2025, covers financial advisory services for a potential Go-Public Transaction and managing the proposed public offering. Celly Nutrition plans to use the capital to accelerate marketing, retail, and direct-to-consumer sales development of unbuzzd™.
Quantum BioPharma (NASDAQ: QNTM) ha annunciato che il suo licenziatario Celly Nutrition, sviluppatore di unbuzzd™ (una bevanda che accelera il metabolismo dell'alcol), ha ingaggiato una importante banca d'investimento di New York per raccogliere fino a 10 milioni di dollari USD ed esplorare una IPO su una borsa US maggiore.
Quantum BioPharma possiede 25,71% di Celly Nutrition e riceve una royalty del 7% sulle vendite di unbuzzd™ fino a raggiungere i 250 milioni di dollari, dopo di che scende al 3% in perpetuo. L'azienda conserva tutti i diritti di sviluppare prodotti simili per scopi farmaceutici e medici.
La Lettera di Impegno firmata il 4 febbraio 2025 copre i servizi di consulenza finanziaria per una potenziale transazione di quotazione in Borsa e la gestione della proposta di offerta pubblica. Celly Nutrition prevede di utilizzare il capitale per accelerare lo sviluppo del marketing, del retail e delle vendite dirette al consumatore di unbuzzd™.
Quantum BioPharma (NASDAQ: QNTM) anunció que su licenciatario Celly Nutrition, desarrollador de unbuzzd™ (una bebida que acelera el metabolismo del alcohol), ha contratado a un importante banco de inversión de Nueva York para recaudar hasta 10 millones de dólares USD y explorar una oferta pública inicial en una bolsa estadounidense importante.
Quantum BioPharma posee 25.71% de Celly Nutrition y recibe una regalía del 7% sobre las ventas de unbuzzd™ hasta alcanzar los 250 millones de dólares, después de lo cual se reduce al 3% en perpetuidad. La empresa retiene todos los derechos para desarrollar productos similares para usos farmacéuticos y médicos.
La Carta de Compromiso firmada el 4 de febrero de 2025, cubre los servicios de asesoría financiera para una posible transacción de salida a bolsa y la gestión de la oferta pública propuesta. Celly Nutrition planea utilizar el capital para acelerar el marketing, el retail y el desarrollo de ventas directas al consumidor de unbuzzd™.
퀀텀 바이오파마 (NASDAQ: QNTM)는 라이센스 파트너인 셀리 뉴트리션이(가) (알코올 대사를 가속화하는 음료) unbuzzd™의 개발자인 유명한 뉴욕 투자은행과 계약을 체결하여 최대 1,000만 달러 USD를 모금하고 주요 미국 거래소에서 IPO를 탐색하고 있다고 발표했습니다.
퀀텀 바이오파마는 셀리 뉴트리션의 25.71%를 소유하고 있으며 unbuzzd™ 판매에서 7%의 로열티를 수취합니다. 이 수치는 2억 5천만 달러에 도달한 후 영구적으로 3%로 감소합니다. 회사는 제약 및 의료 용도를 위한 유사 제품 개발에 대한 모든 권리를 보유하고 있습니다.
2025년 2월 4일에 서명된 계약서는 잠재적인 상장 거래를 위한 재정 자문 서비스와 제안된 공모 관리 서비스를 다룹니다. 셀리 뉴트리션은 이 자본을 이용해 unbuzzd™의 마케팅, 소매 및 소비자 직접 판매 개발을 가속화할 계획입니다.
Quantum BioPharma (NASDAQ: QNTM) a annoncé que son licencié Celly Nutrition, développeur de unbuzzd™ (une boisson qui accélère le métabolisme de l'alcool), a engagé une banque d'investissement de premier plan à New York pour lever jusqu'à 10 millions de dollars USD et explorer une introduction en bourse sur une grande bourse américaine.
Quantum BioPharma détient 25,71% de Celly Nutrition et perçoit une royalties de 7% sur les ventes de unbuzzd™ jusqu'à atteindre 250 millions de dollars, après quoi elle passe à 3% en permanence. L'entreprise conserve tous les droits de développer des produits similaires à des fins pharmaceutiques et médicales.
La Lettre d'engagement signée le 4 février 2025 couvre les services de conseil financier pour une éventuelle opération de mise en bourse et la gestion de l'offre publique proposée. Celly Nutrition prévoit d'utiliser le capital pour accélérer le marketing, le commerce de détail et le développement des ventes directes aux consommateurs de unbuzzd™.
Quantum BioPharma (NASDAQ: QNTM) gab bekannt, dass sein Lizenznehmer Celly Nutrition, Entwickler von unbuzzd™ (einem Getränk, das den Alkoholmetabolismus beschleunigt), eine führende Investmentbank aus New York beauftragt hat, um bis zu 10 Millionen USD zu beschaffen und einen Börsengang an einer großen US-Börse zu prüfen.
Quantum BioPharma besitzt 25,71% von Celly Nutrition und erhält eine 7%ige Lizenzgebühr auf den Verkauf von unbuzzd™, bis 250 Millionen Dollar erreicht sind; danach sinkt sie auf 3% in alle Ewigkeit. Das Unternehmen behält alle Rechte, um ähnliche Produkte für pharmazeutische und medizinische Zwecke zu entwickeln.
Das am 4. Februar 2025 unterzeichnete Engagement-Schreiben deckt Finanzberatungsdienste für eine potenzielle Börseneinführung und die Verwaltung des vorgeschlagenen öffentlichen Angebots ab. Celly Nutrition plant, das Kapital zur Beschleunigung des Marketings, des Einzelhandels und der Direktvertrieb-Entwicklung von unbuzzd™ zu nutzen.
- Owns 25.71% stake in Celly Nutrition
- 7% royalty agreement on unbuzzd™ sales up to $250M, then 3% perpetually
- Retains 100% rights for pharmaceutical/medical applications
- Potential value increase from Celly's planned $10M capital raise and IPO
- None.
Insights
This strategic move represents a significant value-creation opportunity for Quantum BioPharma shareholders. The dual-track approach of capital raise and IPO exploration provides flexibility while potentially accelerating unbuzzd's market penetration. The tiered royalty structure (
The management team's credentials are particularly compelling. Having former Coca-Cola VP John Duffy as CEO and ex-Celsius Holdings CEO Gerry David as Board Co-Chair brings invaluable industry expertise and distribution network access. Their track record in scaling beverage brands is especially relevant given Celsius's successful trajectory from startup to billion-dollar valuation.
The retention of pharmaceutical rights by Quantum represents a hidden asset, effectively creating two separate commercialization pathways: consumer beverages through Celly and potential medical applications through Quantum. This dual-market strategy could unlock significant additional value.
The timing of this move aligns well with current market conditions, where functional beverages are seeing strong consumer demand and premium valuations. The successful US market launch in 2024 provides proof-of-concept, potentially reducing IPO execution risk and supporting higher valuations during the capital raise.
TORONTO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that its licensee Celly Nutrition Corporation, the company behind unbuzzdTM – the scientifically-proven and game-changing beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms –announced that it has engaged a leading New York Investment Bank to raise up to
Quantum BioPharma Ltd. retains ownership of
Celly Nutrition Corp. signed, on February 4, 2025, a Letter of Engagement (“LOE”) with the Investment Bank to provide general financial advisory and investment banking services to the company to:
| (a) | advise the Company on matters relating to an uplisting to a major U.S. exchange, reverse merger into a public company or other transaction that results in the Company’s listing on a major U.S. exchange (each, a “Go-Public Transaction”); | |
| (b) | act as the exclusive managing underwriter and sole book running manager in connection with a proposed follow-on public offering of up to | |
John Duffy, CEO of Celly Nutrition stated, “This is an important milestone for Celly Nutrition and unbuzzd. Having successfully launched unbuzzd in the US market in 2024, our focus in 2025 is to raise additional capital which will enable Celly Nutrition to accelerate unbuzzd’s marketing, retail, and direct-to-consumer sales development, and to expand the availability of unbuzzd to meet growing demand.” Mr. Duffy has more than two decades experience in leadership positions in the beverage industry, including as former VP of Marketing Assets and VP of National Sales at Coca-Cola Company.
Gerry David, Celly Board Co-Chair and former CEO of Celsius Holdings with their bestselling energy drink Celsius Energy, added, “I am confident that we have found the perfect Investment Banking partner to advise and guide Celly Nutrition as we work towards a capital raise and initial public offering. There is so much interest in unbuzzd, we want to give retail investors and markets the opportunity to participate in our success and to be part of the excitement surrounding unbuzzd.”
About Quantum BioPharma Ltd.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented UNBUZZD™ and spun out its OTC version to a company, Celly Nutrition Corp. (“Celly Nutrition”), led by industry veterans. Quantum BioPharma retains ownership of
About Celly Nutrition Corporation
Celly Nutrition, a non-trading but fully reporting public issuer, stands as a pioneering force in the wellness and recovery supplement landscape. unbuzzd has been developed by a world-class R&D team in pharmacology and medicine, with a commitment to innovation and quality. A proprietary blend of vitamins, minerals, and herbs, unbuzzd helps your body process alcohol faster, restore mental alertness, and improve cognition so you can drink responsibly and drink refreshingly. unbuzzd appeals to a broad target audience of alcohol consumers who want to have a good time, be in control, and still feel great the next day.
Scientifically backed by a recently completed double-blind, randomized, placebo-controlled crossover design clinical trial, unbuzzd dramatically accelerates alcohol metabolism, speeds the reduction of blood alcohol concentration, restores mental clarity, and reduces the symptoms of intoxication, impairment and hangover. Key findings from the clinical trial include:
- Accelerated Alcohol Metabolism: unbuzzd dramatically and rapidly reduced blood alcohol concentration in study participants. The rate at which BAC was lowered was, on average for most participants, more than 40 percent faster within 30 minutes of consuming unbuzzd compared to control subjects. This faster reduction of BAC after consuming unbuzzd was both statistically significant compared to placebo and was observed at each subsequent measurement of BAC over a four-hour period.
- Rapid Improvements in Alertness: Study participants reported statistically significant improvement in alertness as soon as 30 minutes after consuming unbuzzd. Participants felt more alert and made fewer cognitive errors within 30 minutes of consuming unbuzzd, significantly outperforming placebo results.
- Rapid Improvements in Physiologic Changes due to Intoxication: unbuzzd lessened the elevation in heart rate and the drop in blood pressure that often accompanies alcohol intoxication, stabilizing both. This result was statistically significant.
- Reduced Perceived Impairment and Mental Fatigue: unbuzzd helped alleviate perceived impairment and mental fatigue caused by alcohol intoxication.
- Hangover Relief: Participants in this study noted a statistically significant reduction in hangover symptoms. This included reduced cognitive and physical impairment, and reduced headache compared to placebo results, at both four hours (67 percent reduction in headache severity) and eight hours after consuming unbuzzd.
- No Side Effects: unbuzzd was well-tolerated by all study participants, with no reported adverse side effects.
The full press release of the clinical trial can be found here.
unbuzzd ready-to-mix powder sticks are available in 3-pack and 18-pack formats at https://unbuzzd.com. unbuzzdTM is a registered trademark of Celly Nutrition Corp.
Individual results may vary. unbuzzd is a dietary supplement. Consuming unbuzzd after alcohol ingestion does not permit you to operate a vehicle. Drink responsibly. DO NOT DRINK AND DRIVE.
Forward-Looking Information
Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include statements related to such.
Forward-looking information in this press release are based on certain assumptions and expected future events.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward- looking information, except as required by applicable law.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811
Investor Relations
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
QNTM@mzgroup.us
www.mzgroup.us
FAQ
What percentage of Celly Nutrition does Quantum BioPharma (QNTM) own?
What are the royalty terms for QNTM from unbuzzd™ sales?
How much capital is Celly Nutrition planning to raise in 2025?
What rights does QNTM retain for pharmaceutical applications of unbuzzd™?
When did Celly Nutrition sign the Letter of Engagement for the capital raise?
